🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 19 of 857 · Phase 3 first, then by program name

  1. Anifrolumab

    AstraZeneca

    Cutaneous Lupus Erythematosus

    phase 3 other active

    1 trial

  2. Anifrolumab

    AstraZeneca AB

    Moderate-to-severe Systemic Lupus Erythematosus (SLE)

    phase 3 small molecule active

    1 trial

  3. Anifrolumab

    AstraZeneca

    Systemic Lupus Erythematosus

    phase 3 mab active

    1 trial

  4. Anifrolumab

    AstraZeneca

    Lupus Nephritis

    phase 3 small molecule active

    1 trial

  5. Anifrolumab

    AstraZeneca

    Active Systemic Lupus Erythematosus

    phase 3 mab completed

    3 trials

  6. Anifrolumab, Anifrolumab Placebo

    AstraZeneca AB

    Polymyositis or dermatomyositis according to 2017 EULAR / ACR classification criteria

    phase 3 small molecule active

    1 trial

  7. Anifrolumab, Matching placebo solution for injection in aPFS; 0.8 mL fill volume

    AstraZeneca AB

    Cutaneous Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  8. Anodal tDCS

    United Therapeutics Europe Ltd

    Stroke

    phase 3 other active

    1 trial

  9. Anterior Capsulotomy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Obsessive-Compulsive Disorder

    phase 3 other active

    1 trial

  10. Anti C5 Complement mAb Placebo, Ultomiris 1,100 mg/11 mL concentrate for solution for infusion

    Alexion Europe SAS

    Immunoglobulin A Nephropathy (IgAN)

    phase 3 small molecule active

    1 trial

  11. Anti C5 Complement mAb Placebo, Ultomiris 300 mg/30 mL concentrate for solution for infusion

    Alexion Europe SAS

    Hematopoietic stem cell transplant-associated thrombotic microangiopathy

    phase 3 small molecule active

    1 trial

  12. Anti-PD-1 antibody drug named Serplulimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Locally Advanced Rectal Cancer (LARC)

    phase 3 small molecule active

    1 trial

  13. Anti-thymocyte globulin

    Ultragenyx UK Limited

    Aplastic Anemia

    phase 3 small molecule completed

    1 trial

  14. Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg

    Takeda

    Major Depressive Disorder

    phase 3 small molecule completed

    3 trials

  15. Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method

    Baxalta Innovations GmbH

    Hemophilia A

    phase 3 mab completed

    1 trial

  16. Antihemophilic Factor (Recombinant), Porcine Sequence (BAX 802)

    Takeda

    Hemophilia A

    phase 3 mab terminated

    1 trial

  17. Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)

    Takeda

    Hemophilia A

    phase 3 small molecule completed

    1 trial

  18. Antiplatelet (Aspirin, Dipyridamole, clopidogrel)

    United Therapeutics Europe Ltd

    Cervical Artery Dissection

    phase 3 small molecule completed

    1 trial

  19. Apalutamide

    Janssen Cilag International NV

    Metastatic Castrate-sensitive Prostate Cancer

    phase 3 small molecule active

    1 trial

  20. Apitox - pure honeybee toxin

    Apimeds Pharmaceuticals US

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  21. Apitox, purified honeybee toxin, lyophilized in saline

    Apimeds Pharmaceuticals US

    Osteoarthritis of the Knee

    phase 3 mab completed

    1 trial

  22. Apixaban

    United Therapeutics Europe Ltd

    Cerebral Vein Thrombosis

    phase 3 small molecule completed

    2 trials

  23. Apremilast 20mg

    Amgen

    Psoriatic Arthritis

    phase 3 small molecule completed

    1 trial

  24. Apremilast, Apremilast, Apremilast

    Amgen

    Behçet’s disease is a chronic, relapsing, multisystem inflammatory disorder of unknown etiology characterized by 4 major symptoms (oral aphthous ulcers, genital ulcers, skin lesions, and ocular lesions) and occasionally by 5 minor symptoms (arthritis, gastrointestinal ulcers, epididymitis, vascular lesions, and central nervous system [CNS] symptoms) (Cho, 2012). Juvenile idiopathic arthritis is a heterogeneous group of chronic inflammatory disorders that initially presents in children by the age of 16 years. It refers to arthritis of at least 6 weeks duration of unknown etiology that begins in children less than 16 years old. Juvenile idiopathic arthritis has an annual incidence of 2 to 20 cases per 100 000 population and a prevalence of 16 to 150 cases per 100 000 population. It is an autoimmune disorder marked by abnormalities of immune responses (Adelowo, 2010).

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources